Rahul Mathur
Analyst · Wells Fargo Securities. You may now ask your question
Thanks, Luc. I'd like to begin with our financial results for the second quarter. Let me start with some highlights on Slide 5. As Luc mentioned, we continue to execute in our product businesses and delivered excellent financial results at the high-end of our revenue and earnings expectations while continuing to strengthen our balance sheet. We've adopted ASC 606 using the modified retrospective method, which does not restate prior periods, but rather runs the cumulative effect of the adoption through retained earnings as the beginning balance sheet adjustment. Any comparison between our results under ASC 606 and prior results under ASC 605 is not an accurate way to track our company's progress. We will continue to provide operational metrics such as licensing billings to give our investors better insight into our operational performance. We delivered revenue of $59.9 million and licensing billings of $60.7 million at the high-end of our expectations. We have a very strong balance sheet and ended the quarter with cash, cash equivalents and marketable securities of $486.1 million, up from the previous quarter due to cash from operations of $62 million, our best quarterly performance in over 10 years. Our continued execution on our strategy and our operational discipline have yielded excellent financial results and a strong balance sheet that affords us flexibility on our strategic initiatives. Now, let me talk you through some revenue details on Slide 6. Revenue for the second quarter was $59.9 million at the high-end of our expected range due to another record quarter for our buffer chip business. Royalty revenue for the second quarter was $17 million, while licensing billings was $60.7 million. The difference between licensing billings and royalty revenue primarily relates to timing as we don't always recognize revenue in the same quarter, we bill our customers. Going into additional detail; our product revenue was $31.7 million, consisting primarily of our buffer chip business. Our contracted other revenue was $11.2 million, consisting primarily of our silicon IP business. Our silicon IP business was down quarter over quarter as expected due to the timing of customer engagements. As you saw in our press release, we expect this to return in Q3. For the year, there's roughly $35 million of our silicon IP business that's being reflected in our licensing billings. This is almost double what we expected in our Analyst Day last year due to the structure of our contracts and acquisition accounting. Let me walk you through our non-GAAP income statement on Slide 7. Along with our excellent revenue performance in Q2, we again exceeded our profitability targets. Total operating expenses, including COGS for the quarter came in at $59.5 million, operating expenses of $47.7 million were lower than our expectations due to lower spending on employee-related expenses. With higher revenue and disciplined execution on spending, our profit was nicely above our expectations. We ended the quarter with headcount of 670 flat from 665 in the previous quarter. Under ASC 606, we recorded $3.7 million of interest income related to the financing component of our fixed fee licensing arrangement for which we have recognized revenue but not yet received payment. We incurred $0.8 million of interest expense primarily associated with our convertible notes. This was offset by incremental interest income related to the return on our cash and investment portfolio. After adjusting for non-cash interest expense on a convertible note, this resulted in non-GAAP interest and other income for the second quarter of $3.8 million. Excluding the interest income related to the financing components related to ASC 606, this would have been $0.1 million. Using an assumed flat rate of 24% for non-GAAP pre-tax income, our non-GAAP net income for the quarter was $3.2 million. Now, let me turn to the balance sheet details on Slide 8. Over the past several years, we've built a very strong balance sheet. Cash, cash equivalents and marketable securities totaled $486.1 million, up significantly from the previous quarter, primarily through cash from operations of $62 million. As I mentioned previously, this is our best performance in over 10 years. In the first half of this year, we've generated nearly $100 million of cash from operations. At the end of Q2, we had contract assets worth $444.5 million, which reflects the net present value of unbilled AR-related licensing arrangements for which the company has no future performance obligations. I expect this number to continue to trend down as we bill and collect for these contracts. It's important to note that this metric doesn't represent the entire value of our existing licensing arrangements, as several customers have royalty-based agreements that allow us to recognize revenue each quarter under ASC 606. Second quarter CapEx was $14.9 million and depreciation was $4.8 million. We delivered $47.1 million free cash flow in the quarter. Looking forward, I expect roughly $19 million of CapEx for the third quarter and roughly $36 million for the full year of 2020, a third of which is related to the relocation of our headquarters facility. I also expect depreciation of roughly $5 million for the third quarter, and roughly $20 million for the full year of 2020. Our strategic refocus on our core markets and operational efficiencies has set a solid foundation for our company. Our predictable high margin licensing business has put us in a position to come out of the current environment stronger than ever. We continue to build cash and have limited debt with a disciplined financial approach that is, built capital while investing in growth, we are well-positioned to grow both organically and inorganically. Our historical and ongoing investments in technology R&D has helped us build a patent portfolio that is foundational to our industry. Our historical agreements, including those we signed this quarter position us well for our licensing renewals in the upcoming periods. Now, let me turn to our guidance for the third quarter on Slide 9. As a reminder, our forward-looking guidance reflects our current best estimates. And our actual results could differ materially from what I'm about to review. In addition to the financial outlook under ASC 606, we've also been providing information on licensing billings, which is an operational metric that reflect amounts invoiced to our licensing customers during the period adjusted for certain differences. As you see in the supplemental information, we provided on Slide 13 of our earnings deck, licensing billings closely correlates with what we'd historically reported as royalty revenue under ASC 605. We feel that we are very well positioned in the market, but remain cautious regarding a near-term outlook due to the lack of visibility created by COVID-19. With that said, under ASC 606, we expect revenue in the third quarter between $54 million and $60 million. We expect royalty revenue between $9 million and $15 million. We also expect licensing billings between $55 million and $61 million. Quarter over quarter, we expect growth in our silicon IP business to offset small productions and patent licensing. We expect Q3 non-GAAP total operating costs and expenses, which includes COGS to be between $64 million and $60 million as we continue to invest in programs. Under ASC 606, non-GAAP operating results for the third quarter is expected to be between zero and a $10 million loss. For non-GAAP interest and other income and expense, which exclude the interest income related to ASC 606, we expect this to be approximately zero which includes $0.6 million of interest expense related to the notes due in 2023. Based on the tax legislation passed at the end of 2017, we expect our pro forma tax rate in 2020 to remain consistent with our 2019 pro forma tax rate of roughly 24%. The 24% is higher than the statutory rate of 21%, primarily due to higher tax rates in our foreign jurisdiction. As a reminder, we pay roughly $20 million of cash taxes each year driven primarily by our licensing agreements with our partners in Korea. We expect non-GAAP taxes to be between a benefit of zero and $2 million in Q3. We expect our Q3 share count to be roughly $116 million basic and diluted shares outstanding. This leads you to between a non-GAAP loss per share of $0.07 and $0.00 for the quarter. While we don't provide guidance beyond Q3, as a reminder in Q4, we will see our last step down related to one of our large licensing agreements. With no other changes, this represents incrementally better profit than current consensus estimates for Q4. As I've mentioned previously, in the coming years, I expect licensing billings to stabilize at the same level we expect to see in 2020. Our product growth will then provide leverage on both the top line and the bottom line. Let me finish with a summary on Slide 10. We are proud of the excellent performance by our team and the progress we continue to make against our strategic initiatives to drive long term profitable growth. While we understand that ASC 606 added a level of complexity to our financial reporting, it's important to reiterate that the underlying financial strength of our business remains strong, reflected in our demonstrated ability to generate cash. We have refocused our product portfolio around Rambus's core strength in the semiconductor industry, improved our operational efficiency and profitability, generated solid cash from operations and leveraged our strong balance sheet to support our strategic initiatives. We continue to focus on our core markets and are well-positioned to come out of the current environment stronger than ever. Before I open up the call to Q&A, I would, once again, like to thank our employees for their amazing resilience during these uncertain times. Everyone, please, stay safe and take care of yourself and your families. With that, I'll turn the call back to our operator to begin Q&A. Could we please have our first question?